41 research outputs found
Magnetized Anisotropic Dark Energy Models in Barber's Second Self-Creation Theory
No full textThe present paper deals with Bianchi type IX cosmological model with magnetized anisotropic dark energy by using Barber's selfcreation theory. The energy momentum tensor consists of anisotropic fluid with EoS parameter and a uniform magnetic field of energy density . In order to obtain the exact solution we have assumed that dark energy components and the components of magnetic field interact minimally and obey the law of conservation of energy momentum tensors. We have also used the special law of variation for the mean generalized Hubble parameter and power law relation between scalar field and scale factor. Some physical and kinematical properties of the models have been discussed
Magnetized Anisotropic Dark Energy Models in Barber’s Second Self-Creation Theory
No full textThe present paper deals with Bianchi type IX cosmological model with magnetized anisotropic dark energy by using Barber’s self-creation theory. The energy momentum tensor consists of anisotropic fluid with EoS parameter ω and a uniform magnetic field of energy density ρB. In order to obtain the exact solution we have assumed that dark energy components and the components of magnetic field interact minimally and obey the law of conservation of energy momentum tensors. We have also used the special law of variation for the mean generalized Hubble parameter and power law relation between scalar field and scale factor. Some physical and kinematical properties of the models have been discussed
The pharmacological profile of TOP1288, a narrow spectrum kinase inhibitor in clinical development as an anti-inflammatory treatment for ulcerative colitis
No full textA first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
No full textTOP1288 a novel narrow spectrum kinase inhibitor (NSKI), selectively targets key kinases fundamental to inflammatory cell signalling in innate and adaptive immune responses: p38-alpha MAP kinase, Src family kinases (Src and Lck) and Syk. The present phase 1b study was designed to evaluate TOP1288's safety, tolerability, PK and PD in ulcerative colitis patients
P359 A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration
No full textA first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
No full textTOP1288 a novel narrow spectrum kinase inhibitor (NSKI), selectively targets key kinases fundamental to inflammatory cell signalling in innate and adaptive immune responses: p38-alpha MAP kinase, Src family kinases (Src and Lck) and Syk. The present phase 1b study was designed to evaluate TOP1288's safety, tolerability, PK and PD in ulcerative colitis patients
A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration
No full text
